Published in Ochsner J on January 01, 2014
Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Improved retroviral vectors for gene transfer and expression. Biotechniques (1989) 19.48
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem (1988) 3.34
Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun (1988) 2.06
Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res (2003) 1.90
Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther (2000) 1.86
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol (2002) 1.60
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol (2009) 1.55
Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol (2002) 1.28
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol (2006) 1.26
Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer (2002) 1.20
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol (2010) 1.00
Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes. Cancer Res (2005) 0.98
Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today (1997) 0.97
Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol (2006) 0.95
Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res (2001) 0.95
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer (2006) 0.91
Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Transpl Immunol (1996) 0.89
Lack of galactose-alpha-1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol (2004) 0.88
Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer (2011) 0.86
Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol (1994) 0.86
Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res (2005) 0.84
Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol Immunother (2004) 0.83
Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes. Cancer Immunol Immunother (2005) 0.83
Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity. J Immunother (2008) 0.80
Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res (1998) 0.79
Antibody-dependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation (1994) 0.79
Suppression of Lewis lung tumor development in alpha 1,3 galactosyltransferase knock-out mice. Anticancer Res (2004) 0.77
Chimeric retroviral helper virus and picornavirus IRES sequence to eliminate DNA methylation for improved retroviral packaging cells. J Virol (2000) 0.77
Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy. J Autoimmune Dis (2005) 0.76
Primary amyloidosis of the breast presenting as a solitary nodule: case report and review of the literature. Ochsner J (2014) 0.82
Palliative Resection of a Giant Mesenteric Desmoid Tumor. Ochsner J (2015) 0.75
Recurrent angiomatoid fibrous histiocytoma: a case report and review of the literature. Ochsner J (2014) 0.75
Anesthetic Considerations for Intraoperative Radiation Therapy. Ochsner J (2015) 0.75
Melanoma in Situ Treated with Topical Imiquimod for Management of Persistently Positive Margins: A Review of Treatment Methods. Ochsner J (2015) 0.75